Vaderis Therapeutics AG is a clinical stage biotech focussing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020.
- https://vaderis.com/
- +41 79 592 20 05
- info@vaderis.com
- Nicholas Benedict, CEO